Legionnaire’s more fatal with biologics
Patients on biologic therapies are at increased risk of Legionnaire’s disease and considerably more likely to die from it if they are infected, say Australian researchers.
Their review of over 100 cases of Legionella pneumonia in patients taking biologics showed 19% of those who contracted the disease died of it, compared with reported figures for the general population of just 2% to 6%.
Twelve percent of the survivors needed treatment in an intensive care unit.
Over 70% of infected patients were being treated